| 1 |
34551206 | Dipeptidyl peptidase-4 inhibitor and insulin combination treatment in type 2 diabetes and chronic kidney disease: A meta-analysis. | 2022 Mar |
2 |
| 2 |
35043090 | Enhanced endocytosis elevated virulence and severity of SARS-CoV-2 due to hyperglycemia in type 2 diabetic patients. | 2022 Mar |
1 |
| 3 |
35050311 | Cardiovascular Effects of Incretin-Based Therapies: Integrating Mechanisms With Cardiovascular Outcome Trials. | 2022 Feb 1 |
2 |
| 4 |
35164839 | Impact of DPP-4 inhibitors on plasma levels of BNP and NT-pro-BNP in type 2 diabetes mellitus. | 2022 Feb 14 |
1 |
| 5 |
35211246 | Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment. | 2022 Feb 15 |
1 |
| 6 |
35242880 | Safety Assessment of Glucose-Lowering Drugs and Importance of Structured Education during Ramadan: A Systematic Review and Meta-Analysis. | 2022 |
1 |
| 7 |
35566779 | The Effects of Dipeptidyl Peptidase 4 Inhibitors on Renal Function in Patients with Type 2 Diabetes Mellitus. | 2022 May 9 |
1 |
| 8 |
35582467 | Glucose lowering does not necessarily reduce cardiovascular risk in type 2 diabetes. | 2022 Apr 26 |
4 |
| 9 |
32310854 | Vildagliptin vs. insulin treatment alone in diabetic acute coronary syndrome patients. | 2021 Jan |
1 |
| 10 |
32662092 | Effect of dipeptidyl peptidase-4 inhibitors on complement activation. | 2021 Mar |
1 |
| 11 |
32979231 | Efficacy and safety of a sodium-glucose co-transporter-2 inhibitor versus placebo as an add-on therapy for people with type 2 diabetes inadequately treated with metformin and a dipeptidyl peptidase-4 inhibitor: a systematic review and meta-analysis of randomised controlled trials. | 2021 Feb |
2 |
| 12 |
33045957 | Recent Medicinal Chemistry Approach for the Development of Dipeptidyl Peptidase IV Inhibitors. | 2021 |
1 |
| 13 |
33162074 | Molecular basis of the anti-diabetic properties of camel milk through profiling of its bioactive peptides on dipeptidyl peptidase IV (DPP-IV) and insulin receptor activity. | 2021 Jan |
1 |
| 14 |
33408313 | In patients with type 2 diabetes the presence of Hashimoto's thyroiditis reduces the beneficial effect of dipeptidyl peptidase-4 inhibitor on plasma glucose control. | 2021 May 28 |
2 |
| 15 |
33514826 | Dipeptidyl peptidase 4 promotes peritoneal fibrosis and its inhibitions prevent failure of peritoneal dialysis. | 2021 Jan 29 |
1 |
| 16 |
33520110 | Novel glucose-lowering drugs for non-alcoholic fatty liver disease. | 2021 Jan 15 |
1 |
| 17 |
33562528 | Renoprotective Effects of DPP-4 Inhibitors. | 2021 Feb 5 |
1 |
| 18 |
33594477 | Pharmacogenetics of novel glucose-lowering drugs. | 2021 Jun |
1 |
| 19 |
33669354 | Assessing Scientific Soundness and Translational Value of Animal Studies on DPP4 Inhibitors for Treating Type 2 Diabetes Mellitus. | 2021 Feb 16 |
2 |
| 20 |
33765180 | Impact of high glucose levels and glucose lowering on risk of ischaemic stroke: a Mendelian randomisation study and meta-analysis. | 2021 Jul |
1 |
| 21 |
33949781 | Glucose-lowering action through targeting islet dysfunction in type 2 diabetes: Focus on dipeptidyl peptidase-4 inhibition. | 2021 Jul |
3 |
| 22 |
34124273 | Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways. | 2021 |
2 |
| 23 |
34203048 | A Comprehensive Review and Perspective on Natural Sources as Dipeptidyl Peptidase-4 Inhibitors for Management of Diabetes. | 2021 Jun 20 |
4 |
| 24 |
34258291 | The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Dipeptydilpeptidase-4 Inhibitors on Blood Pressure and Cardiovascular Complications in Diabetes. | 2021 |
1 |
| 25 |
34388297 | Acute effect of add-on therapy with tofogliflozin, a sodium glucose co-transporter 2 inhibitor, on 24-hours glucose profile and glycaemic variability evaluated by continuous glucose monitoring in patients with type 2 diabetes receiving dipeptidyl peptidase-4 inhibitors. | 2021 Nov |
4 |
| 26 |
34428715 | A review upon medicinal perspective and designing rationale of DPP-4 inhibitors. | 2021 Sep 15 |
1 |
| 27 |
34439553 | Pathophysiological Association between Diabetes Mellitus and Endothelial Dysfunction. | 2021 Aug 18 |
2 |
| 28 |
34489627 | Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus. | 2021 |
2 |
| 29 |
34549042 | Beneficial effects of posttransplant dipeptidyl peptidase-4 inhibitor administration after pancreas transplantation to improve β cell function. | 2021 Sep |
2 |
| 30 |
34580086 | Diabetes, Drug Treatment, and Mortality in COVID-19: A Multinational Retrospective Cohort Study. | 2021 Dec |
3 |
| 31 |
34733107 | Pleiotropic Benefits of DPP-4 Inhibitors Beyond Glycemic Control. | 2021 |
1 |
| 32 |
34830194 | Incretins in the Therapy of Diabetic Kidney Disease. | 2021 Nov 15 |
1 |
| 33 |
34945051 | Low Screening Rates Despite a High Prevalence of Significant Liver Fibrosis in People with Diabetes from Primary and Secondary Care. | 2021 Dec 9 |
1 |
| 34 |
30463420 | Recently isolated antidiabetic hydrolysates and peptides from multiple food sources: a review. | 2020 |
1 |
| 35 |
31300870 | Degranulation of human cytotoxic lymphocytes is a major source of proteolytically active soluble CD26/DPP4. | 2020 Feb |
8 |
| 36 |
31385198 | DPP-4 Inhibitors: Renoprotective Potential and Pharmacokinetics in Type 2 Diabetes Mellitus Patients with Renal Impairment. | 2020 Feb |
2 |
| 37 |
31529097 | Sitagliptin Decreases Visceral Fat and Blood Glucose in Women With Polycystic Ovarian Syndrome. | 2020 Jan 1 |
1 |
| 38 |
31693275 | Role of endogenous glucagon-like peptide-1 enhanced by vildagliptin in the glycaemic and energy expenditure responses to intraduodenal fat infusion in type 2 diabetes. | 2020 Mar |
1 |
| 39 |
31706956 | Metabolism of GIP and the contribution of GIP to the glucose-lowering properties of DPP-4 inhibitors. | 2020 Mar |
1 |
| 40 |
31774618 | Potential linkage between dipeptidyl peptidase-4 inhibitor use and the risk of pancreatitis/pancreatic cancer. | 2020 Jul |
1 |
| 41 |
31789451 | Persistent whole day meal effects of three dipeptidyl peptidase-4 inhibitors on glycaemia and hormonal responses in metformin-treated type 2 diabetes. | 2020 Apr |
4 |
| 42 |
31813365 | Mining of potential dipeptidyl peptidase-IV inhibitors as anti-diabetic agents using integrated in silico approaches. | 2020 Nov |
1 |
| 43 |
31858859 | The effect of dipeptidyl peptidase-4 inhibitor and glucagon-like peptide-1 receptor agonist in gestational diabetes mellitus: a systematic review. | 2020 May |
1 |
| 44 |
31891536 | DPP4 deletion in adipose tissue improves hepatic insulin sensitivity in diet-induced obesity. | 2020 May 1 |
1 |
| 45 |
31911667 | Identification of osteoclast-osteoblast coupling factors in humans reveals links between bone and energy metabolism. | 2020 Jan 7 |
2 |
| 46 |
32061923 | Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions. | 2020 May |
1 |
| 47 |
32301442 | Sitagliptin Inhibits Extracellular Matrix Accumulation and Proliferation in Lung Fibroblasts. | 2020 Apr 17 |
1 |
| 48 |
32362346 | An Assessment of Pharmacokinetic Interaction Between Lobeglitazone and Sitagliptin After Multiple Oral Administrations in Healthy Men. | 2020 Jun |
1 |
| 49 |
32390941 | Receptor-Mediated Bioassay Reflects Dynamic Change of Glucose-Dependent Insulinotropic Polypeptide by Dipeptidyl Peptidase 4 Inhibitor Treatment in Subjects With Type 2 Diabetes. | 2020 |
2 |
| 50 |
32422444 | Serum Dipeptidyl peptidase-4 level is related to adiposity in type 1 diabetic adolescents. | 2020 Jul - Aug |
2 |